Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metabolic Response in Patients with Post-Treatment Lyme Disease Symptoms/Syndrome

ABSTRACT:

ORGANISM(S): Homo Sapiens

TISSUE(S): Blood

DISEASE(S): Lyme Disease

PROVIDER: ST001391 | MetabolomicsWorkbench |

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome.

Project description: Not available

| S-EPMC8492154 | biostudies-literature

Longitudinal transcriptome profiling of post-treatment Lyme disease syndrome

Project description:Most Lyme disease patients treated with appropriate antibiotics recover rapidly and completely, but a minority of patients develop persistent symptoms correlating with disseminated disease, a greater severity of illness at presentation, and delayed antibiotic therapy. When lingering or recurrent symptoms are associated with a functional decline and persist for greater than 6 months, patients are considered to meet clinical criteria for post-treatment Lyme disease syndrome (PTLDS), although the exact molecular mechanisms underlying this condition remain unknown. We performed longitudinal whole transcriptome sequencing of PTLDS patients' immune cells. No immune mechanism specific to PTLDS were uncovered to date.

2019-02-15 | GSE77929 | GEO

Weight gain during tuberculosis treatment increases the risk of post-tuberculosis metabolic syndrome.

Project description: Not available

| S-EPMC12676555 | biostudies-literature

Peripheral blood gene expression profiles in metabolic syndrome, coronary artery disease and type 2 diabetes

Project description:Gene expression in peripheral blood is shown sufficient to differentiate patients with metabolic disorders from control. The signatures of metabolic syndrome, coronary artery disease and type 2 diabetes also have significant overlap. Microarrays were performed on 35 subjects in the following groups: control (n=9), rheumatoid arthritis (n=6), metabolic syndrome (n= 6), coronary artery disease (n=6) and type 2 diabetes (n=8). Intensity values for each array were normalized to a sum of 10,000.

2010-08-12 | E-GEOD-23561 | biostudies-arrayexpress

Seroprevalence of Antibodies against Tick-Borne Pathogens in Czech Patients with Suspected Post-Treatment Lyme Disease Syndrome.

Project description: Not available

| S-EPMC8619037 | biostudies-literature

Metabolic Reprogramming in Retinoblastoma Patients: Treatment Naive Active Retinoblastoma Versus Regressed Tumors Post-Treatment.

Project description: Not available

| S-EPMC12697687 | biostudies-literature

Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response

Project description: Not available

| S-EPMC12860420 | biostudies-literature

Metabolic syndrome clustering patterns and the association with cardiovascular disease among post-menopausal Korean women.

Project description: Not available

| S-EPMC11442489 | biostudies-literature

Post-epidemic eosinophilia myalgia syndrome associated with L-Tryptophan

Project description:Eosinophilia–myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. The EMS epidemic in 1989 was linked to L-tryptophan consumption originating from a single source. Following the Food and Drug Administration (FDA) ban on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been published since the FDA ban was lifted in 2005. We report the clinical, histopathological and immunogenetic features of a new case of L-tryptophan-associated EMS along with evidence of activated transforming growth factor-ß and interleukin-4 signaling in the lesional skin. 6 samples were analyzed to include EMS patient and two replicates along with three normal controls

2012-01-28 | E-GEOD-26934 | biostudies-arrayexpress

Individual Diet Modification Reduces the Metabolic Syndrome in Patients Before Pharmacological Treatment.

Project description: Not available

| S-EPMC8234117 | biostudies-literature